Literature DB >> 12794796

Improvement in Sjögren's syndrome following therapy with rituximab for marginal zone lymphoma.

Bradley G Somer1, Donald E Tsai, Lisa Downs, Barry Weinstein, Stephen J Schuster.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2003        PMID： 12794796     DOI： 10.1002/art.11109

Source DB:  PubMed          Journal:  Arthritis Rheum        ISSN： 0004-3591


× No keyword cloud information.
  18 in total

1.  Successful treatment of a patient with primary Sjögren's syndrome with Rituximab.

Authors:  Troels Ring; Maria Kallenbach; Jeppe Praetorius; Søren Nielsen; Birgitte Melgaard
Journal:  Clin Rheumatol       Date:  2005-11-08       Impact factor: 2.980

Review 2.  Conventional therapy of Sjogren's syndrome.

Authors:  Clio P Mavragani; Haralampos M Moutsopoulos
Journal:  Clin Rev Allergy Immunol       Date:  2007-06       Impact factor: 8.667

Review 3.  Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2007.

Authors:  D E Furst; F C Breedveld; J R Kalden; J S Smolen; G R Burmester; J Sieper; P Emery; E C Keystone; M H Schiff; P Mease; P L C M van Riel; R Fleischmann; M H Weisman; M E Weinblatt
Journal:  Ann Rheum Dis       Date:  2007-11       Impact factor: 19.103

Review 4.  [Current therapeutic options in Sjögren's syndrome].

Authors:  A Hansen; T Dörner
Journal:  Z Rheumatol       Date:  2010-02       Impact factor: 1.372

5.  Controversies on rituximab therapy in sjögren syndrome-associated lymphoproliferation.

Authors:  Luca Quartuccio; Martina Fabris; Sara Salvin; Marta Maset; Ginevra De Marchi; Salvatore De Vita
Journal:  Int J Rheumatol       Date:  2010-01-28

6.  Tolerance and efficacy of rituximab and changes in serum B cell biomarkers in patients with systemic complications of primary Sjögren's syndrome.

Authors:  Raphaèle Seror; Christelle Sordet; Loic Guillevin; Eric Hachulla; Charles Masson; Marc Ittah; Sophie Candon; Véronique Le Guern; Achille Aouba; Jean Sibilia; Jacques-Eric Gottenberg; Xavier Mariette
Journal:  Ann Rheum Dis       Date:  2006-09-01       Impact factor: 19.103

7.  Should rituximab be considered as the first-choice treatment for severe autoimmune rheumatic diseases?

Authors:  Claudio Galarza; Diana Valencia; Gabriel J Tobón; Luis Zurita; Rubén D Mantilla; Ricardo Pineda-Tamayo; Adriana Rojas-Villarraga; Juan C Rueda; Juan-Manuel Anaya
Journal:  Clin Rev Allergy Immunol       Date:  2008-02       Impact factor: 8.667

Review 8.  Successful treatment of relapsing autoimmune pancreatitis in primary Sjögren's syndrome with rituximab: report of a case and review of the literature.

Authors:  Juan C Rueda; Carolina Duarte-Rey; Nohemi Casas
Journal:  Rheumatol Int       Date:  2009-01-11       Impact factor: 2.631

Review 9.  Hepatitis C virus-related lymphoproliferative disorders: an overview.

Authors:  Anna-Linda Zignego; Carlo Giannini; Clodoveo Ferri
Journal:  World J Gastroenterol       Date:  2007-05-07       Impact factor: 5.742

10.  Ultrasound assessment of salivary glands in patients with primary Sjögren's syndrome treated with rituximab: Quantitative and Doppler waveform analysis.

Authors:  Sandrine Jousse-Joulin; Valérie Devauchelle-Pensec; Johanne Morvan; Bruno Guias; Yvon Pennec; Jacques-Olivier Pers; Capucine Daridon; Christophe Jamin; Yves Renaudineau; Isabelle Quintin Roué; Béatrice Cochener; Luc Bressollette; Pierre Youinou; Alain Saraux
Journal:  Biologics       Date:  2007-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.